Aptamer Group PLC Aptamer Group and PinotBio extend collaboration
23 May 2022 - 4:01PM
RNS Non-Regulatory
TIDMAPTA
Aptamer Group PLC
23 May 2022
23 May 2022
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Aptamer Group and PinotBio extend collaboration for the
development of Optimer(R)-drug conjugates
- Four new Optimer-drug conjugates will be developed targeting different cancer diseases
- Initial results show Aptamer's and PinotBio's technologies can
be combined with good effect to generate targeted cancer
treatments
Aptamer Group plc (AIM: APTA), the developer of novel Optimer
(R) binders to enable innovation in the life sciences industry, is
pleased to announce that it has extended its collaboration
agreement with PinotBio (Gyeonggi-do, Korea), a clinical-stage
oncology-focused biotechnology company, to develop four new
Optimer-drug conjugates for use as precision chemotherapeutics.
The partnership commenced in June 2021, targeting haematological
cancers, and the first phase of the project has been successfully
completed. This demonstrated the viability of combining Optimer
technology with PinotBio's proprietary linker-payload antibody-drug
conjugate (ADC) platform for targeted drug delivery to cancer cells
and the effective killing of the target cells by chemotherapy.
Aptamer and PinotBio will now work together to develop Optimer-drug
conjugates, as a novel format ADC alternative, to four specified
non-blood-based cancer targets: Nectin-4, Tissue Factor, CEACAM5
and CD73. The developed assets will be jointly owned by both
parties, with each party retaining ownership over the individual
components of the conjugate and if successful will open
opportunities for downstream value creation in the form of
licensing fees, milestones and or royalties.
The Optimer binder in the Optimer-drug conjugate acts as a
specific targeting vehicle for the simple conjugation of payloads
and their targeted delivery to the site-of-action. PinotBio's
linker-payload system has shown the potential to overcome tumour
resistance and safety concerns, even at relatively high doses in
non-human primates. Targeting the drug directly to the
site-of-action with this combination of technologies could limit
the side effects of chemotherapeutic drugs in non-cancerous tissues
and provide a higher concentration at the site-of-action and yield
a larger therapeutic index compared with alternatives.
Aptamer will develop Optimer vehicles to the specified targets
and provide these to PinotBio for use with their payload and linker
technologies. PinotBio will generate the full Optimer-drug
conjugates and perform initial animal studies to evaluate the
conjugate molecules and their potential to progress as clinical
candidates. Each party will cover its own development costs in
support of the generation of these therapeutic assets.
Dr Arron Tolley, Chief Executive Officer of Aptamer Group,
commented: "The data from the first phase of this work, combining
our Optimer technology with PinotBio's linker and chemotherapeutic
payloads, were very promising and demonstrated the power of Optimer
binders to develop effective enabling technologies resulting in
drug-conjugate development targeting different disease states. As a
result, we are very excited to be able to extend this collaboration
with PinotBio to develop Optimer-drug conjugates as novel cancer
treatments. We are encouraged by the potential of these novel
format drugs to make a difference and improve the quality of cancer
patient lives through reduced side effects, and we look forward to
providing updates in due course."
Dr Dooyoung Jung, Chief Executive Officer of PinotBio, commented
: "The development of Optimer-drug conjugates, as next-generation
ADCs, in collaboration with Aptamer Group highlights the
compatibility of PINOT-ADC(TM) , with antibodies as well as
advanced technologies, such as Optimer. The tailored targeting
methods of Optimer for drug delivery combined with PINOT-ADC holds
promise for smaller, improved drug delivery with a greater
therapeutic index that will improve treatment for cancer patients
globally."
- ENDS -
For further information, please contact:
Aptamer Group plc
+44 (0) 1904 56 7790
Dr Arron Tolley - CEO /
Eleanor Brown - CFO
Consilium Strategic Communications +44 (0) 20 3709 5700
Matthew Neal / Chris Welsh / Lucy Featherstone
aptamergroup@consilium-comms.com
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its
proprietary Optimer(R) platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers through the use of its
proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global antibody market is
currently worth over $145bn. Optimer binders are engineered to
address many of the issues found with alternative affinity
molecules, such as antibodies, and offer new, innovative solutions
to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global
pharma companies, diagnostic development companies, and research
institutes covering a range of targets and applications with the
objective of establishing royalty-bearing licenses. Through the
unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions
that support discovery and development across the Life
Sciences.
About Reach announcements
Reach is an investor communication service aimed at assisting
listed and unlisted (including AIM quoted) companies to distribute
media only / non-regulatory news releases such as marketing
messages, corporate and product information into the public domain.
An RNS Regulatory announcement is required to be notified under the
AIM Rules for Companies.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFFAEDIFFIF
(END) Dow Jones Newswires
May 23, 2022 02:01 ET (06:01 GMT)
Aptamer (LSE:APTA)
Historical Stock Chart
From Apr 2024 to May 2024
Aptamer (LSE:APTA)
Historical Stock Chart
From May 2023 to May 2024